# Alfasigma S.p.A. clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Alfasigma S.p.A. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alfasigma S.p.A.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/alfasigma-s-p-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2026 | NCT07882537 | STUDY OF THE EFFECTS OF L. CASEI DG® (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS. | Alfasigma S.p.A. | Not applicable | Completed | Gut Microbiota Modulation | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882537) |
| April 28, 2026 | NCT07554495 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis... | Alfasigma S.p.A. | Phase 3 | Recruiting | Polyarticular Course Juvenile Idiopathic Arthritis | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554495) |
| April 27, 2026 | NCT07553182 | OLE Study With Filgotinib in JIA | Alfasigma S.p.A. | Phase 3 | Recruiting | Juvenile Idiopathic Arthritis (JIA) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553182) |
| March 7, 2025 | NCT06865417 | A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis | Alfasigma S.p.A. | Phase 3 | Recruiting | Ulcerative Colitis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06865417) |
| January 24, 2024 | NCT06222034 | Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) | Alfasigma S.p.A. | Phase 1 | Terminated | Juvenile Idiopathic Arthritis | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06222034) |
| April 18, 2023 | NCT05817942 | Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) | Alfasigma S.p.A. | Observational | Active not recruiting | Ulcerative Colitis | 509 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05817942) |
| March 27, 2023 | NCT05785611 | A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis | Alfasigma S.p.A. | Phase 3 | Active not recruiting | Axial Spondyloarthritis | 495 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05785611) |
| February 13, 2023 | NCT05724069 | Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). | Alfasigma S.p.A. | Phase 2 | Completed | Chronic Intestinal Pseudo-obstruction | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05724069) |
| April 12, 2022 | NCT05323591 | Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France | Alfasigma S.p.A. | Observational | Completed | Rheumatoid Arthritis | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05323591) |
| December 9, 2021 | NCT05150587 | Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea | Alfasigma S.p.A. | Phase 2 | Completed | Papulopustular Rosacea | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05150587) |
| May 4, 2021 | NCT04871919 | Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis | Alfasigma S.p.A. | Observational | Active not recruiting | Rheumatoid Arthritis | 1,304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04871919) |
| March 6, 2019 | NCT03864978 | Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test | Alfasigma S.p.A. | Phase 2 | Unknown | Papulopustular Rosacea | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03864978) |
| May 25, 2018 | NCT03537157 | A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention | Alfasigma S.p.A. | Phase 2 | Terminated | Crohn Disease | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03537157) |
| March 19, 2018 | NCT03469050 | Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. | Alfasigma S.p.A. | Phase 2/3 | Terminated | Diverticulitis | 193 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03469050) |
| June 15, 2017 | NCT03188328 | Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of... | Alfasigma S.p.A. | Phase 1 | Terminated | Inoperable Solid Tumors or Lymphomas | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03188328) |
| April 11, 2017 | NCT03106922 | A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children | Alfasigma S.p.A. | Phase 3 | Unknown | Bowel Preparation Before Colonoscopy | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03106922) |
| January 19, 2017 | NCT03025308 | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | Alfasigma S.p.A. | Phase 3 | Completed | Rheumatoid Arthritis | 2,731 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03025308) |
| September 26, 2016 | NCT02914535 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Alfasigma S.p.A. | Phase 3 | Completed | Ulcerative Colitis | 1,173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02914535) |
| March 3, 2015 | NCT02376972 | Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis | Alfasigma S.p.A. | Phase 2 | Terminated | BACTERIAL VAGINOSIS | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02376972) |
| April 10, 2014 | NCT02110784 | Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria | Alfasigma S.p.A. | Phase 2 | Terminated | Malaria, Vivax | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02110784) |
| February 3, 2014 | NCT02053324 | AvidinOX + \[177Lu\]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer | Alfasigma S.p.A. | Phase 1 | Terminated | Liver Metastases | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02053324) |
| November 9, 2011 | NCT01467726 | Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects | Alfasigma S.p.A. | Phase 1 | Completed | Alzheimer's Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01467726) |
| September 11, 2007 | NCT00528073 | Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease | Alfasigma S.p.A. | Phase 2 | Completed | Crohn's Disease | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00528073) |
| October 24, 2006 | NCT00391820 | Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial) | Alfasigma S.p.A. | Phase 2 | Completed | Chronic Constipation | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00391820) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 9 |
| Terminated | 7 |
| Recruiting | 3 |
| Active not recruiting | 3 |
| Unknown | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 3 |
| Arthritis, Juvenile | 3 |
| Colitis, Ulcerative | 3 |
| Crohn Disease | 2 |
| Rosacea | 2 |
| Malaria, Vivax | 1 |
| Lymphoma | 1 |
| Alzheimer Disease | 1 |
| Constipation | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Diverticulitis | 1 |
| Colic | 1 |
| Vaginosis, Bacterial | 1 |
| Axial Spondyloarthritis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Audiology clinics in the United States](https://specstream.ai/data/businesses/audiology-clinics/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Siding contractors in the United States](https://specstream.ai/data/businesses/siding-contractors/united-states)
- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
